Navigation Links
Pharmion and MethylGene Initiate Phase One Combination Clinical Trial with MGCD0103 and Taxotere(R) in Patients with Solid Tumors
Date:10/10/2007

ignation from the U.S. Food and Drug Administration (FDA) and has been designated an orphan medicinal product by the European Medicines Agency (EMEA) for the treatment of Hodgkin's lymphoma.

About Pharmion

Pharmion is a leading global oncology company focused on acquiring, developing and commercializing innovative products for the treatment of hematology and oncology patients in the U.S., Europe and additional international markets. Pharmion has a number of products on the market including the world's first approved epigenetic drug, Vidaza(R), a DNA demethylating agent. For additional information about Pharmion, please visit the company's website at http://www.pharmion.com.

About MethylGene

MethylGene Inc. (TSX: MYG) is a publicly-traded biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for cancer. The Company's lead product, MGCD0103, is an oral isotype-selective HDAC inhibitor presently in multiple clinical trials for solid tumors and hematological malignancies, including Phase II monotherapy and Phase I/II combination trials with Vidaza(R), Gemzar(R) and Taxotere(R). MGCD265 is an oral kinase inhibitor targeting the c-Met, Tie-2, Ron and VEGF receptor tyrosine kinases. In addition, MethylGene has several preclinical programs: MGCD290 an HDAC inhibitor in combination with azoles for fungal infections; an HDAC program for Huntington's disease; a sirtuins program for cancer; and a beta-lactamase program to overcome antibiotic resistance. MethylGene's development and commercialization partners include Pharmion Corporation, Taiho Pharmaceutical and EnVivo Pharmaceuticals. Please visit our website at http://www.methylgene.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements relating to the planned
'/>"/>

SOURCE Pharmion Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
2. Pharmion to Present Clinical Data on Commercial and Pipeline Products at 2007 American Society of Clinical Oncology (ASCO) Meeting
3. Malvern initiates European user group meetings for chemical imaging
4. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
5. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
6. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/12/2014)... , Sept. 12, 2014 /PRNewswire-iReach/ -- 9 th ... 22-24, 2014 – Bethesda, MD ... http://www.fdanews.com/9thInspectionsSummitEarlyBird   Photo - http://photos.prnewswire.com/prnh/20140912/145652 ... for the next inspection than to get a glimpse ... during and after an inspection. Come to ...
(Date:9/12/2014)... DUBLIN , Sept. 12, 2014 ... addition of the "Global Medical Technologies Market ... Medical technology is a collective term for ... used to ensure good health. The Global Medical ... anaesthetic and respiratory technology, In vitro diagnostics technology, ...
(Date:9/12/2014)... 2014  Genomic Health, Inc. (Nasdaq: GHDX ... results from a health economic analysis suggesting that use ... in a significant reduction in direct medical costs and ... side effects of unnecessary treatment.  "By ... conventional measures, as demonstrated in this analysis, the Oncotype ...
Breaking Medicine Technology:FDAnews Announces: Early Bird Registration Discount Ends Sept.19 for 9th Annual Inspections Summit, Oct. 22-24, 2014 2FDAnews Announces: Early Bird Registration Discount Ends Sept.19 for 9th Annual Inspections Summit, Oct. 22-24, 2014 3Global Medical Technologies Market 2014-2018: Key Vendors are GE, Johnson & Johnson, Medtronic, Roche and Siemens 2Global Medical Technologies Market 2014-2018: Key Vendors are GE, Johnson & Johnson, Medtronic, Roche and Siemens 3Genomic Health Announces Publication of Colon Cancer Cost-Effectiveness Study in PharmacoEconomics 2Genomic Health Announces Publication of Colon Cancer Cost-Effectiveness Study in PharmacoEconomics 3Genomic Health Announces Publication of Colon Cancer Cost-Effectiveness Study in PharmacoEconomics 4Genomic Health Announces Publication of Colon Cancer Cost-Effectiveness Study in PharmacoEconomics 5
(Date:9/14/2014)... each night may mean you,re less likely to take time off ... study included more than 3,700 people in Finland, aged 30 to ... Those who slept less than six hours or more than nine ... from work due to illness, the investigators found. People with the ... were those who slept between seven and eight hours a night. ...
(Date:9/14/2014)... Top10BestSEOHosting.com always offers truly reliable information for worldwide ... the site has announced that Arvixe ( http://www.arvixe.com/6883.html ... Hosting suppliers in the current market. , Arvixe ... provider, and the company’s reputation for reliability remains ... for its flexible hosting packages, decent uptime record ...
(Date:9/14/2014)... (PRWEB) September 14, 2014 A new DePuy ... Schulte LLC on behalf of a Franklin County, Ohio ... hip implant. The metal-on-metal hip lawsuit filed against Johnson ... the Ohio man was 40 years old when the Pinnacle ... No. 3:14-cv-02428-K) According to the hip implant lawsuit ...
(Date:9/14/2014)... Washington (PRWEB) September 14, 2014 School requires ... Washington law requires that they be screened only for far ... at twenty feet away. When their eyes do not ... their books, they will, at best, avoid reading; at ... brains and their ability to learn. Children who cannot ...
(Date:9/13/2014)... Recently, an experienced supplier of wedding dresses ... new collection of eggplant evening dresses . At ... rates, up to 58% off. According to the company’s ... 23. , The company’s new items are available ... plus size, modest, sexy outfits and so on. iFitDress.com ...
Breaking Medicine News(10 mins):Health News:A Good Night's Sleep May Mean a Good Day's Work 2Health News:Top10BestSEOHosting.com: The Best Linux Web Hosting Suppliers Now Unveiled 2Health News:Wright & Schulte LLC Files Another DePuy Pinnacle Hip Lawsuit Purporteding Risky Revision Surgery Needed Due To Failure of Metal-on-Metal Hip Replacement 2Health News:Wright & Schulte LLC Files Another DePuy Pinnacle Hip Lawsuit Purporteding Risky Revision Surgery Needed Due To Failure of Metal-on-Metal Hip Replacement 3Health News:Wright & Schulte LLC Files Another DePuy Pinnacle Hip Lawsuit Purporteding Risky Revision Surgery Needed Due To Failure of Metal-on-Metal Hip Replacement 4Health News:Wright & Schulte LLC Files Another DePuy Pinnacle Hip Lawsuit Purporteding Risky Revision Surgery Needed Due To Failure of Metal-on-Metal Hip Replacement 5Health News:Cheap Eggplant Evening Dresses Now Announced By Experienced Company iFitDress.com 2
... Safety Technology, HONOLULU, Aug. 5 ... Medical Center will equip 100 additional medical-surgical,floor ... Systems,(LifeBed), bringing the total number LifeBed,s available ... any bed into a LifeBed, which,invisibly tracks ...
... - Her Son May Need a Liver ... Transplant, ... come true. As she heads to the Mrs.,America* competition in Tucson, Arizona on ... her 10-year-old son, Connor will be,healthy again. Connor was born with a deadly ...
... Communication, Training and Disaster ... Preparedness ... a leading IP solutions provider offering telepresence and VoIP,services to business ... by St. Vincent Catholic Medical,Centers of New York for a variety ...
... First Half of 2008 Over 2007, WEST PALM ... MDF ), a leading provider of healthcare,services in ... quarter ended June 30, 2008., On July 28, ... ended,June 30, 2008, the company,s Medicare Advantage HMO and ...
... (NYSE: SCR ), a leading manufacturer and supplier ... biotech,product Endu in China, today reported unaudited financial results ... -- Total revenue increased to RMB436.2 million (US$63.6 ... representing a 30.4% year-over-year growth;, -- Net income ...
... $72 ... Million ... System Building Strong Market Momentum, ST. LOUIS, Aug. 5 Stereotaxis, Inc. ... for the recent second quarter increased 36% to $10.7,million compared with $7.8 million ...
Cached Medicine News:Health News:Hoana Medical Expands Partnership With The Queen's Medical Center to Improve Patient Safety 2Health News:Hoana Medical Expands Partnership With The Queen's Medical Center to Improve Patient Safety 3Health News:Mrs. California Uses Her Title to Save Lives - She Now Heads to Mrs. America Competition 2Health News:Mrs. California Uses Her Title to Save Lives - She Now Heads to Mrs. America Competition 3Health News:St. Vincent's Catholic Medical Centers of New York Select Telanetix Telepresence Solution 2Health News:St. Vincent's Catholic Medical Centers of New York Select Telanetix Telepresence Solution 3Health News:Metropolitan Health Networks Reports 2008 Second Quarter Results 2Health News:Metropolitan Health Networks Reports 2008 Second Quarter Results 3Health News:Metropolitan Health Networks Reports 2008 Second Quarter Results 4Health News:Metropolitan Health Networks Reports 2008 Second Quarter Results 5Health News:Metropolitan Health Networks Reports 2008 Second Quarter Results 6Health News:Metropolitan Health Networks Reports 2008 Second Quarter Results 7Health News:Metropolitan Health Networks Reports 2008 Second Quarter Results 8Health News:Metropolitan Health Networks Reports 2008 Second Quarter Results 9Health News:Metropolitan Health Networks Reports 2008 Second Quarter Results 10Health News:Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2008 Results 2Health News:Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2008 Results 3Health News:Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2008 Results 4Health News:Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2008 Results 5Health News:Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2008 Results 6Health News:Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2008 Results 7Health News:Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2008 Results 8Health News:Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2008 Results 9Health News:Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2008 Results 10Health News:Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2008 Results 11Health News:Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2008 Results 12Health News:Stereotaxis Reports Record Second Quarter Revenue 2Health News:Stereotaxis Reports Record Second Quarter Revenue 3Health News:Stereotaxis Reports Record Second Quarter Revenue 4Health News:Stereotaxis Reports Record Second Quarter Revenue 5Health News:Stereotaxis Reports Record Second Quarter Revenue 6Health News:Stereotaxis Reports Record Second Quarter Revenue 7Health News:Stereotaxis Reports Record Second Quarter Revenue 8
...
EDM Lumbar Drainage Kit with and without Bioglide are fabricated of radiopaque (barium impregnated) silicone tubing, and are packaged with stainless steel stylets inserted in the lumen....
... external ventricular drainage set (EVD ... fluid for external ventricular drainage. ... combination with a ventricular catheter ... 3XL probe from the Aesculap ...
... Bactiseal EVD Catheter system is ... catheter for external CSF drainage ... on catheter tube surfaces. Treated ... Impregnation Process, it reduces the ...
Medicine Products: